Lawrence A. Loeb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lawrence A. Loeb has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Edward J. Fox
Department of Pathology, University of Washington, Seattle, WA, 98195, USA
6 shared publications Ashwini S. Kamath-Loeb
From the Departments of Pathology and Biochemistry, The Gottstein Memorial Cancer Research Laboratory, University of Washington, Seattle, Washington 98195
3 shared publicationsJiang-Cheng Shen
Department of Pathology, University of Washington, Seattle, USA
3 shared publicationsMarc J. Prindle
Joseph Gottstein Memorial Laboratory, Department of Pathology, University of Washington, Seattle, Washington 98195, USA
3 shared publicationsMichael W. Schmitt
The §Department of Biochemistry, University of Washington, Seattle, Washington 98195-7350
3 shared publications- Brendan F. Kohrn
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, USA
2 shared publications
Latest Publications
- Open Access
Ultra-sensitive sequencing for cancer detection reveals progressive clonal selection in normal tissue over a century of human lifespan
High accuracy next-generation DNA sequencing promises a paradigm shift in early cancer detection by enabling the identification of mutant cancer molecules in minimally-invasive body fluid samples. We demonstrate 80% sensitivity for ovarian cancer detection using ultra-accurate Duplex Sequencing to identify TP53 mutations in uterine lavage. However, in addition to tumor DNA, we also detect low frequency TP53 mutations in nearly all lavages from women with and without cancer. These mutations increase with age and share the selection traits of clonal TP53 mutations commonly found in human tumors. We show that low frequency TP53 mutations exist in multiple healthy tissues, from newborn to centenarian, and progressively increase in abundance and pathogenicity with older age across tissue types. Our results illustrate that subclonal cancer evolutionary processes are a ubiquitous part of normal human aging and great care must be taken to distinguish tumor-derived, from age-associated mutations in high sensitivity clinical cancer diagnostics.
Open AccessUltra-sensitive sequencing for cancer detection reveals progressive clonal selection in normal tissue over a century of human lifespan
High accuracy next-generation DNA sequencing promises a paradigm shift in early cancer detection by enabling the identification of mutant cancer molecules in minimally-invasive body fluid samples. We demonstrate 80% sensitivity for ovarian cancer detection using ultra-accurate Duplex Sequencing to identify TP53 mutations in uterine lavage. However, in addition to tumor DNA, we also detect low frequency TP53 mutations in nearly all lavages from women with and without cancer. These mutations increase with age and share the selection traits of clonal TP53 mutations commonly found in human tumors. We show that low frequency TP53 mutations exist in multiple healthy tissues, from newborn to centenarian, and progressively increase in abundance and pathogenicity with older age across tissue types. Our results illustrate that subclonal cancer evolutionary processes are a ubiquitous part of normal human aging and great care must be taken to distinguish tumor-derived, from age-associated mutations in high sensitivity clinical cancer diagnostics.
- 10 August 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (35) , 9415-9420
Accurate RNA consensus sequencing for high-fidelity detection of transcriptional mutagenesis-induced epimutations
Significance: Epimutations arising from transcriptional mutagenesis have been hypothesized to contribute to viral and bacterial evolution, drug resistance, and age-related diseases, including cancer and neurodegeneration. However, methodology limitations have inhibited progress toward elucidating the contributions of epimutations to cellular evolution and survival in vivo. Recent efforts to overcome these limitations remain constrained by artifacts arising during RNA library preparation. We present accurate RNA consensus sequencing (ARC-seq), an accurate, high-throughput RNA sequencing method that effectively eliminates errors introduced during RNA library preparation and sequencing and represents a major advance over previous methods. ARC-seq will enable investigations of the causal roles of transcriptional fidelity and epimutations in multiple fields, including viral evolution, bacterial resistance, and age-related diseases, such as cancer and neurodegeneration.
- 10 August 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (35) , 9415-9420
Accurate RNA consensus sequencing for high-fidelity detection of transcriptional mutagenesis-induced epimutations
Significance: Epimutations arising from transcriptional mutagenesis have been hypothesized to contribute to viral and bacterial evolution, drug resistance, and age-related diseases, including cancer and neurodegeneration. However, methodology limitations have inhibited progress toward elucidating the contributions of epimutations to cellular evolution and survival in vivo. Recent efforts to overcome these limitations remain constrained by artifacts arising during RNA library preparation. We present accurate RNA consensus sequencing (ARC-seq), an accurate, high-throughput RNA sequencing method that effectively eliminates errors introduced during RNA library preparation and sequencing and represents a major advance over previous methods. ARC-seq will enable investigations of the causal roles of transcriptional fidelity and epimutations in multiple fields, including viral evolution, bacterial resistance, and age-related diseases, such as cancer and neurodegeneration.
- Open Access
- 31 July 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (15) , 4569-4578
Decreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells
Rare stochastic mutations may accumulate during dormancy of stem-like cells, but technical limitations in DNA sequencing have limited exploring this possibility. In this study, we employed a recently established deep-sequencing method termed Duplex Sequencing to conduct a genome-wide analysis of mitochondrial (mt) DNA mutations in a human breast stem cell model that recapitulates the sequential stages of breast carcinogenesis. Using this method, we found significant differences in mtDNA among normal stem cells, immortal/preneoplastic cells, and tumorigenic cells. Putative cancer stem-like cell (CSC) populations and mtDNA copy numbers increased as normal stem cells become tumorigenic cells. Transformed cells exhibited lower rare mutation frequencies of whole mtDNA than did normal stem cells. The predicted mtDNA rare mutation pathogenicity was significantly lower in tumorigenic cells than normal stem cells. Major rare mutation types in normal stem cells are C>T/G>A and T>C/A>G transitions, while only C>T/G>A are major types in transformed cells. We detected a total of 1,220 rare point mutations, 678 of which were unreported previously. With only one possible exception (m10342T>C), we did not find specific mutations characterizing mtDNA in human breast CSCs; rather, the mitochondrial genome of CSCs displayed an overall decrease in rare mutations. On the basis of our work, we suggest that this decrease (in particular T>C/A>G transitions), rather than the presence of specific mitochondrial mutations, may constitute an early biomarker for breast cancer detection. Our findings support the hypothesis that the mitochondrial genome is altered greatly as a result of the transformation of normal stem cells to CSCs, and that mtDNA mutation signatures may aid in delineating normal stem cells from CSCs. Cancer Res; 76(15); 4569–78. ©2016 AACR.
- 31 July 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (15) , 4569-4578
Open AccessDecreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells
Rare stochastic mutations may accumulate during dormancy of stem-like cells, but technical limitations in DNA sequencing have limited exploring this possibility. In this study, we employed a recently established deep-sequencing method termed Duplex Sequencing to conduct a genome-wide analysis of mitochondrial (mt) DNA mutations in a human breast stem cell model that recapitulates the sequential stages of breast carcinogenesis. Using this method, we found significant differences in mtDNA among normal stem cells, immortal/preneoplastic cells, and tumorigenic cells. Putative cancer stem-like cell (CSC) populations and mtDNA copy numbers increased as normal stem cells become tumorigenic cells. Transformed cells exhibited lower rare mutation frequencies of whole mtDNA than did normal stem cells. The predicted mtDNA rare mutation pathogenicity was significantly lower in tumorigenic cells than normal stem cells. Major rare mutation types in normal stem cells are C>T/G>A and T>C/A>G transitions, while only C>T/G>A are major types in transformed cells. We detected a total of 1,220 rare point mutations, 678 of which were unreported previously. With only one possible exception (m10342T>C), we did not find specific mutations characterizing mtDNA in human breast CSCs; rather, the mitochondrial genome of CSCs displayed an overall decrease in rare mutations. On the basis of our work, we suggest that this decrease (in particular T>C/A>G transitions), rather than the presence of specific mitochondrial mutations, may constitute an early biomarker for breast cancer detection. Our findings support the hypothesis that the mitochondrial genome is altered greatly as a result of the transformation of normal stem cells to CSCs, and that mtDNA mutation signatures may aid in delineating normal stem cells from CSCs. Cancer Res; 76(15); 4569–78. ©2016 AACR.
- Open Access
- 14 April 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (8) , 2057-2059
Human Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences
The mutator phenotype hypothesis was postulated more than 40 years ago. It was based on the multiple enzymatic steps required to precisely replicate the 6 billion bases in the human genome each time a normal cell divides. A reduction in this accuracy during tumor progression could be responsible for the striking heterogeneity of malignant cells within a tumor and for the rapidity by which cancers become resistant to therapy. Cancer Res; 76(8); 2057–9. ©2016 AACR. See related article by Loeb et al. Cancer Res. 1974;34:2311–21.
- 14 April 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (8) , 2057-2059
Open AccessHuman Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences
The mutator phenotype hypothesis was postulated more than 40 years ago. It was based on the multiple enzymatic steps required to precisely replicate the 6 billion bases in the human genome each time a normal cell divides. A reduction in this accuracy during tumor progression could be responsible for the striking heterogeneity of malignant cells within a tumor and for the rapidity by which cancers become resistant to therapy. Cancer Res; 76(8); 2057–9. ©2016 AACR. See related article by Loeb et al. Cancer Res. 1974;34:2311–21.
- Open Access
- 25 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0136216
Detection of Ultra-Rare Mitochondrial Mutations in Breast Stem Cells by Duplex Sequencing
Long-lived adult stem cells could accumulate non-repaired DNA damage or mutations that increase the risk of tumor formation. To date, studies on mutations in stem cells have concentrated on clonal (homoplasmic) mutations and have not focused on rarely occurring stochastic mutations that may accumulate during stem cell dormancy. A major challenge in investigating these rare mutations is that conventional next generation sequencing (NGS) methods have high error rates. We have established a new method termed Duplex Sequencing (DS), which detects mutations with unprecedented accuracy. We present a comprehensive analysis of mitochondrial DNA mutations in human breast normal stem cells and non-stem cells using DS. The vast majority of mutations occur at low frequency and are not detectable by NGS. The most prevalent point mutation types are the C>T/G>A and A>G/T>C transitions. The mutations exhibit a strand bias with higher prevalence of G>A, T>C, and A>C mutations on the light strand of the mitochondrial genome. The overall rare mutation frequency is significantly lower in stem cells than in the corresponding non-stem cells. We have identified common and unique non-homoplasmic mutations between non-stem and stem cells that include new mutations which have not been reported previously. Four mutations found within the MT-ND5 gene (m.12684G>A, m.12705C>T, m.13095T>C, m.13105A>G) are present in all groups of stem and non-stem cells. Two mutations (m.8567T>C, m.10547C>G) are found only in non-stem cells. This first genome-wide analysis of mitochondrial DNA mutations may aid in characterizing human breast normal epithelial cells and serve as a reference for cancer stem cell mutation profiles.
- 25 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0136216
Open AccessDetection of Ultra-Rare Mitochondrial Mutations in Breast Stem Cells by Duplex Sequencing
Long-lived adult stem cells could accumulate non-repaired DNA damage or mutations that increase the risk of tumor formation. To date, studies on mutations in stem cells have concentrated on clonal (homoplasmic) mutations and have not focused on rarely occurring stochastic mutations that may accumulate during stem cell dormancy. A major challenge in investigating these rare mutations is that conventional next generation sequencing (NGS) methods have high error rates. We have established a new method termed Duplex Sequencing (DS), which detects mutations with unprecedented accuracy. We present a comprehensive analysis of mitochondrial DNA mutations in human breast normal stem cells and non-stem cells using DS. The vast majority of mutations occur at low frequency and are not detectable by NGS. The most prevalent point mutation types are the C>T/G>A and A>G/T>C transitions. The mutations exhibit a strand bias with higher prevalence of G>A, T>C, and A>C mutations on the light strand of the mitochondrial genome. The overall rare mutation frequency is significantly lower in stem cells than in the corresponding non-stem cells. We have identified common and unique non-homoplasmic mutations between non-stem and stem cells that include new mutations which have not been reported previously. Four mutations found within the MT-ND5 gene (m.12684G>A, m.12705C>T, m.13095T>C, m.13105A>G) are present in all groups of stem and non-stem cells. Two mutations (m.8567T>C, m.10547C>G) are found only in non-stem cells. This first genome-wide analysis of mitochondrial DNA mutations may aid in characterizing human breast normal epithelial cells and serve as a reference for cancer stem cell mutation profiles.
- 6 April 2015
- Published by Springer Nature in Nature Methods
- Vol. 12 (5) , 423-425
Sequencing small genomic targets with high efficiency and extreme accuracy
The detection of minority variants in mixed samples requires methods for enrichment and accurate sequencing of small genomic intervals. We describe an efficient approach based on sequential rounds of hybridization with biotinylated oligonucleotides that enables more than 1-million-fold enrichment of genomic regions of interest. In conjunction with error-correcting double-stranded molecular tags, our approach enables the quantification of mutations in individual DNA molecules.
- 6 April 2015
- Published by Springer Nature in Nature Methods
- Vol. 12 (5) , 423-425
Sequencing small genomic targets with high efficiency and extreme accuracy
The detection of minority variants in mixed samples requires methods for enrichment and accurate sequencing of small genomic intervals. We describe an efficient approach based on sequential rounds of hybridization with biotinylated oligonucleotides that enables more than 1-million-fold enrichment of genomic regions of interest. In conjunction with error-correcting double-stranded molecular tags, our approach enables the quantification of mutations in individual DNA molecules.
- 9 October 2014
- Published by Springer Nature in Nature Protocols
- Vol. 9 (11) , 2586-2606
Detecting ultralow-frequency mutations by Duplex Sequencing
The high error rate of NGS methods has limited the ability to accurately detect ultra-low-frequency mutations. Duplex Sequencing reduces the error rate of NGS such that a single nucleotide mutation can be detected in >1×107 wild-type nucleotides. Duplex Sequencing (DS) is a next-generation sequencing methodology capable of detecting a single mutation among >1 × 107 wild-type nucleotides, thereby enabling the study of heterogeneous populations and very-low-frequency genetic alterations. DS can be applied to any double-stranded DNA sample, but it is ideal for small genomic regions of <1 Mb in size. The method relies on the ligation of sequencing adapters harboring random yet complementary double-stranded nucleotide sequences to the sample DNA of interest. Individually labeled strands are then PCR-amplified, creating sequence 'families' that share a common tag sequence derived from the two original complementary strands. Mutations are scored only if the variant is present in the PCR families arising from both of the two DNA strands. Here we provide a detailed protocol for efficient DS adapter synthesis, library preparation and target enrichment, as well as an overview of the data analysis workflow. The protocol typically takes 1–3 d.
- 9 October 2014
- Published by Springer Nature in Nature Protocols
- Vol. 9 (11) , 2586-2606
Detecting ultralow-frequency mutations by Duplex Sequencing
The high error rate of NGS methods has limited the ability to accurately detect ultra-low-frequency mutations. Duplex Sequencing reduces the error rate of NGS such that a single nucleotide mutation can be detected in >1×107 wild-type nucleotides. Duplex Sequencing (DS) is a next-generation sequencing methodology capable of detecting a single mutation among >1 × 107 wild-type nucleotides, thereby enabling the study of heterogeneous populations and very-low-frequency genetic alterations. DS can be applied to any double-stranded DNA sample, but it is ideal for small genomic regions of <1 Mb in size. The method relies on the ligation of sequencing adapters harboring random yet complementary double-stranded nucleotide sequences to the sample DNA of interest. Individually labeled strands are then PCR-amplified, creating sequence 'families' that share a common tag sequence derived from the two original complementary strands. Mutations are scored only if the variant is present in the PCR families arising from both of the two DNA strands. Here we provide a detailed protocol for efficient DS adapter synthesis, library preparation and target enrichment, as well as an overview of the data analysis workflow. The protocol typically takes 1–3 d.
- Open Access
- 1 August 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (31) , 21663-21672
Sphingosine, a Modulator of Human Translesion DNA Polymerase Activity
- 1 August 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (31) , 21663-21672
Open AccessSphingosine, a Modulator of Human Translesion DNA Polymerase Activity
- Open Access
- 30 July 2014
- Published by Springer Nature in Nature
- Vol. 512 (7513) , 143-144
One cell at a time
Single-cell DNA sequencing of two breast-cancer types has shown extensive mutational variation in individual tumours, confirming that generation of genetic diversity may be inherent in how tumours evolve. See Article p.155 Human breast cancers often display intratumour genomic heterogeneity, making clinical diagnosis difficult and complicating the interpretation of research results. This study tackles the problem using a newly developed whole-genome single-cell sequencing technique called nuc-seq that makes use of the natural genome duplication that occurs in the S phase of the cell cycle to achieve 91% mean coverage breadth. The method is applied to sequence single normal and tumour nuclei from an oestrogen-receptor-positive breast cancer and a triple-negative ductal carcinoma. Aneuploid rearrangements emerge as early events, and they remain stable during clonal expansion. In contrast, point mutations appear to evolve gradually, generating extensive clonal diversity. The data also show that no two single tumour cells are genetically identical, raising interesting questions as to the strict definition of a clone.
- 30 July 2014
- Published by Springer Nature in Nature
- Vol. 512 (7513) , 143-144
Open AccessOne cell at a time
Single-cell DNA sequencing of two breast-cancer types has shown extensive mutational variation in individual tumours, confirming that generation of genetic diversity may be inherent in how tumours evolve. See Article p.155 Human breast cancers often display intratumour genomic heterogeneity, making clinical diagnosis difficult and complicating the interpretation of research results. This study tackles the problem using a newly developed whole-genome single-cell sequencing technique called nuc-seq that makes use of the natural genome duplication that occurs in the S phase of the cell cycle to achieve 91% mean coverage breadth. The method is applied to sequence single normal and tumour nuclei from an oestrogen-receptor-positive breast cancer and a triple-negative ductal carcinoma. Aneuploid rearrangements emerge as early events, and they remain stable during clonal expansion. In contrast, point mutations appear to evolve gradually, generating extensive clonal diversity. The data also show that no two single tumour cells are genetically identical, raising interesting questions as to the strict definition of a clone.
- Open Access
- 1 February 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (8) , 5572-5580
A Substitution in the Fingers Domain of DNA Polymerase δ Reduces Fidelity by Altering Nucleotide Discrimination in the Catalytic Site*
- 1 February 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (8) , 5572-5580
Open AccessA Substitution in the Fingers Domain of DNA Polymerase δ Reduces Fidelity by Altering Nucleotide Discrimination in the Catalytic Site*